

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 12, 2025**

ROCKWELL MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-23661
(Commission File Number)

38-3317208
(IRS Employer
Identification No.)

30142 S. Wixom Road, Wixom, Michigan 48393
(Address of principal executive offices, including zip code)

(248) 960-9009
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each exchange on which registered
Common Stock, par value \$0.0001	RMTI	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On November 12, 2025, Rockwell Medical, Inc. made available an updated corporate presentation. A copy of the corporate presentation is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits The following exhibit is being furnished herewith:

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Rockwell Medical, Inc. Corporate Presentation dated November 12, 2025
104	Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROCKWELL MEDICAL, INC.

Date: November 12, 2025

By: /s/ Mark Strobeck
Mark Strobeck
Chief Executive Officer



ROCKWELL
MEDICAL

Investor Presentation

November 12, 2025

RMTI
Nasdaq Listed

Forward-Looking Statements and Non-GAAP Measures

Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, 2024, 2025 and 2026 guidance, future net sales, reliance on capital investments, ability to grow, industry leadership position, total addressable estimated CAGR, reduction of debt, and continued growth. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "can," "could," "would," "develop," "plan," "potential," "predict," "forecast," "project," "plan," "intend," "positioned to," "guidance," "vision," "strategy," or the negatives of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this presentation. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the risk that we do not maintain profitability or achieve net sales, gross margin or adjusted EBITDA guidance targets; the risk that we are unable to achieve our corporate goals and projected milestones, including that we achieve sustained profitability for FY'25 on an adjusted EBITDA basis, grow our concentrates business by adding new customers, expand contracts and partnerships with existing customers, continue to optimize our business through improved processes and expanded automated manufacturing capabilities and complete additional business development opportunities to support strategic objectives; the risk that market opportunities are smaller than estimated, including the estimated total addressable market, including the home dialysis market, and CAGR; the impact of any further increases in raw material, labor, fuel or other input costs, particularly if we are unable to pass these cost increases along to our customers; the risk that we are unable to obtain additional financing and raise capital as necessary to pursue business opportunities; and those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any subsequent reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

This presentation includes certain non-GAAP financial measures. Please see the section entitled "Reconciliation to GAAP Financial measures" in the Appendix for an explanation of management's use of these measures and reconciliations to the most directly comparable GAAP financial measures. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

All data as of September 30, 2025 unless otherwise noted.

Rockwell Medical At A Glance

Business Overview

- Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide.
- Largest supplier of liquid bicarbonate hemodialysis concentrates in the U.S.
- Second largest supplier of acid and dry bicarbonate concentrates in the U.S.
- Total Addressable Market ~\$450M in 2024, estimated CAGR of ~4-6% through 2028^(a).

Financial Metrics

	Three Months Ended September 30, 2025	Nine Months Ended September 30, 2025	2025 Guidance	Current Capitalization	
Net Sales	\$15.9M	\$50.9M	\$65M - \$70M	Share Price ^(b) :	\$1.05
Gross Margin	18%*	17%**	16% - 18%	Market Cap ^(c) :	\$41M
Adjusted EBITDA	\$0.05M	(\$0.6)M	(\$0.5)M - \$0.5M	Total Cash, Cash Equivalents, Investments Available for Sale ^(d) :	\$23.7M
				Total Debt ^(d) :	\$8.7M

^(a) SOURCE: CAGR based on "Rockwell Medical: Concentrates Growth Strategy Report", L.E.K. Consulting LLC (2022). ^(b) Share price at market close on 11/11/25. ^(c) Calculation based on 39,405,302 shares outstanding as of 11/7/25. ^(d) As of 9/30/25.
* Excluding restructuring costs in the third quarter 2025. ** Excluding restructuring costs in 2025.

Executive Management Team



**President and
Chief Executive Officer**
Dr. Mark Strobeck



Chief Financial Officer
Jesse Neri



Chief Legal Officer
Megan Timmins



Chief Commercial Officer
Tim Chole



Chief Operating Officer
Heather Hunter



Corporate Strategy



Provide Customers with the Highest Quality and Most Reliable Products and Services



Diversify our Customer Base and Product Portfolio



Optimize our Business through Continued Manufacturing Improvements



Achieve Sustainable Profitability

Leading Manufacturer and Supplier of Concentrates



Hemodialysis is a Necessity for End Stage Renal Disease Patients

- Approximately 475,000 patients in the U.S. require in-center hemodialysis annually^(a).
- Each patient receives approximately 3 treatments per week, totaling ~150 in-clinic procedures per patient per year.
- Each patient requires 3.3 gallons of concentrate per treatment.



Rockwell is an Indispensable Player

- A leading manufacturer and supplier that has scalability and transportation infrastructure to service the more than 12,000 individual purchasing facilities (including outpatient dialysis clinics and hospitals) in the U.S. and select international markets.
- Largest supplier of liquid bicarbonate hemodialysis concentrates in the U.S.
- Second largest supplier of acid and dry bicarbonate concentrates in the U.S.

(a) 2022 United States Renal Data System (USRDS) Annual Data Report. Published by the Chronic Disease Research Group (CDRG) in partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Department of Health and Human Services (HHS). Accessed January 2023. www.niddk.nih.gov/about-niddk/strategic-plans-reports/usrds.

U.S. In-Center and Acute Care Hemodialysis Concentrates TAM

~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease



SOURCE: CAGR based on "Rockwell Medical: Concentrates Growth Strategy Report", L.E.K. Consulting LLC (2022)

Sample of Dialysis Providers, Hospital Systems, Distributors that Rockwell Services

Dialysis Providers




Hospital Systems



Supplier Partners / Distributors



Rockwell Distributes to 30+ Countries Worldwide



Key Drivers to Diversify our Customer Base and Product Portfolio



Geographic Expansion

Increase market share throughout the U.S. and internationally. Rockwell continues to secure commercial partnerships and seeks additional growth opportunities globally.



Market Consolidation

Several small, regional hemodialysis concentrates manufacturers. Opportunity for consolidation and modernization.



At Home Treatments

At home dialysis and transition care markets have potential to address up to 80% of dialysis TAM. Rockwell believes it is well-positioned to address this expanding market.



Complementary Products

Leverage domain expertise in manufacturing and distribution to expand product portfolio by developing and/or in-licensing products including single-use concentrates and new products.

Financials and Milestones

Third Quarter 2025 Financial Results

	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
<i>(In Thousands, Except Per Share Amounts)</i>				
Net Sales	\$ 15,927	\$ 28,316	\$ 50,912	\$ 76,824
Gross Profit	2,272	6,239	7,817	13,853
Operating Income (Loss)	(1,584)	1,936	(4,293)	1,127
Net Income (Loss)	(1,753)	1,664	(4,760)	276
Adjusted EBITDA**	50	2,798	(630)	3,678
Basic Net Income (Loss) per Share*	\$ (0.05)	\$ 0.05	\$ (0.15)	\$ 0.01
Diluted Net Income (Loss) per Share*	\$ (0.05)	\$ 0.04	\$ (0.15)	\$ 0.01
Adjusted EPS**	\$ 0.00	\$ 0.09	\$ (0.02)	\$ 0.12

* See Note 3 for more details related to Basic and Diluted Weighted Average Shares Outstanding on Form 10-Q filed November 12, 2025.

** See reconciliation to GAAP financial measures in the tables on Slide 17.

2025 Guidance



Net Sales
\$65.0M - \$70.0M



Adjusted EBITDA
\$(0.5)M - \$0.5M



Gross Margin
16% to 18%

* In 2025, Rockwell Medical estimated that it will lose approximately \$34 million of net sales as its largest customer (the "Customer") transitions to another supplier. The Company is still in discussions with the Customer about terms of a potential contract extension and/or future volume commitments to Rockwell Medical. While there can be no assurance that these discussions will yield a successful outcome for Rockwell Medical, the Company is continuing to work closely with the Customer to support its clinics and its patients.

2025 Projected Milestones

- ❑ **Achieve sustained profitability for FY'25 on an adjusted EBITDA basis.**
- ❑ **Grow concentrates business by adding new customers.**
- ❑ **Expand contracts and partnerships with existing customers.**
- ❑ **Continue to optimize our business through improved processes and expanded automated manufacturing capabilities.**
- ❑ **Complete additional business development opportunities to support strategic objectives.**

Why Invest in Rockwell Medical?

- ✓ Experienced Management Team
- ✓ Large and Growing Market Opportunity
- ✓ Revenue-Generating Business
- ✓ Strong Financials
- ✓ Attractive Valuation





 **ROCKWELL**
MEDICAL

www.rockwellmed.com

IR@rockwellmed.com

Reconciliation to GAAP Financial Measures

Non-GAAP Financial Measures

To supplement the Company's financial results presented on a U.S. generally accepted accounting principles ("GAAP") basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operating metrics. The Company believes that the presentation of these non-GAAP financial measures, when viewed with results under GAAP and the accompanying reconciliation, provides supplementary information to analysts, investors, lenders, and the Company's management in assessing the Company's performance and results from period to period. The Company uses these non-GAAP measures internally to understand, manage and evaluate the Company's performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

	Three Months Ended September 30		Nine Months Ended September 30	
	2025	2024	2025	2024
<i>(In Thousands)</i>				
Net Income (Loss)	\$ (1,753)	\$ 1,664	\$ (4,760)	\$ 276
Other expense, net	169	272	467	851
Depreciation and amortization	542	541	1,640	1,633
EBITDA	(1,042)	2,477	(2,652)	2,760
Severance costs	219	-	430	9
Stock-based compensation	532	321	1,360	910
Greer facility closure	341	-	380	-
Deferred license revenue	-	-	(325)	-
Triferic inventory write-off	-	-	178	-
Adjusted EBITDA	\$ 50	\$ 2,798	\$ (630)	\$ 3,678

